Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL: Obeticholic Acid and Atorvastatin in NASH
NCT02633956Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Intercept Pharmaceuticals. Primary endpoints: Effect of Obeticholic Acid on Low-density Lipoprotein (LDL) Concentration at 16 weeks, Effect of Obeticholic Acid on LDL Particle Size at 16 weeks and 1 more. Started Dec 2015; status: completed.
02
Drugs
obeticholic acid
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02633956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633956.